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The varicella-zoster virus (VZV) Oka vaccine offers potential as a recombinant vaccine against other pathogens. In this study, recombinant
simian varicella viruses (rSVV) expressing simian immunodeficiency virus (SIV) envelope (env, gp130) and gag antigens were constructed.
Expression of the SIV env and gag transcripts and antigens in rSVV-infected Vero cells was confirmed. The rSVV-SIVenv and rSVV-SIVgag
viruses replicated as efficiently as wild-type SVV in cell culture. The immunogenicity of rSVV-SIVenv and rSVV-SIVgag was investigated in
immunized vervet monkeys. Humoral immune responses to the SIV gp130 and gag antigens were detected as early as 4 weeks after the initial
immunization with higher antibody titers following a booster immunization. Cellular immune responses against the SIV gp130 antigen were
detected by ELISPOT assay. The rSVV established latent infection in neural ganglia. A subsequent study will evaluate the ability of rSVV
vaccines expressing SIV antigens to protect nonhuman primates against simian AIDS.
© 2007 Elsevier Inc. All rights reserved.Keywords: Varicella-zoster virus; Simian varicella virus; Simian immunodeficiency virus; VaccineIntroduction
Varicella-zoster virus (VZV) causes varicella (chickenpox),
generally a mild rash disease of children, although sometimes a
serious disease of adults and immunosuppressed individuals.
Following the resolution of the primary disease, VZVestablishes
life-long latent infection in neural ganglia. Later in life, usually
in the elderly, the virus may reactivate to cause herpes zoster
(shingles), characterized by unilateral vesicular rash and pain.
Postherpetic neuralgia, an intense and sometimes chronic pain,
may be a complication of herpes zoster.
The live, attenuated VZV Oka vaccine is safe and effective
for preventing childhood varicella. Since its U.S. approval in
1995, the varicella vaccine has become a routine immunization
for pre-school children in the U.S. and the vaccine is also widely
administered in other countries (Grose, 2005). In addition, the
vaccine augments immunity in older adults and may protect the⁎ Corresponding author. Fax: +1 501 686 5359.
E-mail address: graywaynel@uams.edu (W.L. Gray).
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doi:10.1016/j.virol.2007.03.025elderly against herpes zoster and postherpetic neuralgia (Oxman
et al., 2005).
The varicella vaccine is also a candidate vector for delivery of
foreign antigens and immunization against other pathogens
(Arvin et al., 1999). The vaccine offers several advantages as a
recombinant vaccine including an established safety and ef-
ficacy record, a large DNA genome including dispensable
regions which permit insertion of one or more foreign genes, a
host range restricted to humans thus limiting uncontrolled
environmental spread and the ability to induce strong humoral
and cellular immune responses. Previous studies provide
support for the VZV vaccine as a platform to express foreign
genes and to induce immune responses against antigens of other
pathogens including hepatitis B virus, herpes simplex virus
(HSV) and human immunodeficiency virus type one (HIV-1)
(Heineman et al., 2004; Staprans et al., 2004; Shiraki et al., 1991,
2001). Unfortunately, the species specificity of VZVand the lack
of suitable animal models limit adequate evaluation of re-
combinant varicella vaccines.
Simian varicella virus (SVV) infection of nonhuman primates
offers an experimental model to investigate varicella patho-
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2004). SVV and VZV are closely related herpesviruses with
extensive antigenic cross-reactivity and genomes that are similar
in size and gene organization (Fletcher and Gray, 1992; Gray
et al., 2001). In addition, SVV causes in nonhuman primates a
natural disease which mimics VZV clinical symptoms and
pathogenesis (Gray, 2003). Like VZV, SVV establishes latent
infection of neural ganglia and may reactivate to cause se-
condary disease (Mahalingam et al., 1992).
Novel vaccine strategies are urgently needed to resolve the
current HIV-1 acquired immunodeficiency syndrome (AIDS)
epidemic. The simian AIDS model is a useful approach to
evaluate candidate AIDS vaccines. In this report, we demon-
strate construction of recombinant SVV (rSVV) expressing the
simian immunodeficiency virus (SIV) gag and envelope (env,
gp130) antigens and demonstrate the ability of these vaccines to
induce humoral and cellular immune responses to SIV antigens
in immunized vervet monkeys.
Results
Construction of recombinant varicella viruses expressing SIV
env and gag antigens
SVV recombinant viruses expressing the SIV env and gag
genes under the control of the human cytomegalovirus im-Fig. 1. Construction and analysis of rSVV-SIVenv. (A) Confirmation of the SIVenv g
from total cell DNA template isolated from rSVV-SIVenv-infected Vero cells using th
env DNAwas detected by agarose gel electrophoresis. M—100 bp molecular weight m
by RT-PCR analysis. RT-PCR was conducted using two different SIVenv gene prime
included RT (lanes 1 and 3) or did not include RT (lanes 2 and 4). The amplified SIV
weight markers. (C) Detection of SIV env (gp130) antigens in rSVV-SIVenv-infecte
monkey SIV immune serum. (D) Detection of SIV gp130 antigens in Vero cells infecte
cells infected with two different rSVV-SIVenv viruses (lanes 2 and 3), or with wild-mediate early (HCMV IE) promoter/enhancer were constructed
using the SVV cosmid recombination system (Gray and
Mahalingam, 2005). The HCMV-SIVenv-polyA and HCMV-
SIVgag-polyA cassettes were inserted into the SVV genome
within the viral glycoprotein C gene (gC, open reading frame
[ORF] 14). The presence of the SIV env gene within the rSVV-
SIVenv genome was confirmed by PCR using SIV env
oligonucleotide primers and total cell DNA isolated from
rSVV-SIVenv-infected Vero cells (Fig. 1A). The expression of
the SIV env gene was confirmed by reverse-transcriptase (RT)-
PCR detection of SIV env transcripts within total cell RNA
isolated from rSVV-SIVenv-infected Vero cells (Fig. 1B). SIV
env (gp130) antigen expression in rSVV-SIVenv-infected Vero
cells, but not wild-type SVV-infected cells, was demonstrated by
immunofluorescence assay using SIV immune monkey serum
(Fig. 1C). SIV gp160 precursor and gp130 antigens were
detected in rSVV-SIVenv-infected Vero cells by immunoblot
analysis (Fig. 1D).
In like manner, the presence of the SIV gag gene within the
rSVV-SIVgag genome was confirmed by PCR (Fig. 2A) and
gag gene expression demonstrated by RT-PCR detection of SIV
gag transcripts in rSVV-SIVgag infected Vero cells (Fig. 2B).
SIV gag antigen expression in rSVV-SIVgag infected cells was
confirmed by immunofluorescence (Fig. 2C) and immunoblot
(Fig. 2D) analyses using SIV gag specific monoclonal antibody
(mAb).ene in the rSVV-SIVenv genome by PCR analysis. PCR products were amplified
ree different SIVenv oligonucleotide primer sets (lanes 1–3). The amplified SIV
arkers. (B) Detection of SIVenv transcripts in rSVV-SIVenv-infected Vero cells
r sets and total cell RNA template isolated from infected Vero cells and reactions
env cDNAwas detected by agarose gel electrophoresis. M—100 bp molecular
d or wild-type SVV-infected Vero cells by immunofluorescence analysis using
d with a recombinant vaccinia virus (VV) expressing SIVenv (lane 1), or in Vero
type SVV (lane 4) by immunoblot analysis using monkey SIV immune serum.
Fig. 2. Construction and analysis of rSVV-SIVgag. (A) Confirmation of the SIV 1.6 kb gag gene in rSVV-SIVgag by PCR analysis. PCR products were amplified from
total cell DNA template isolated from Vero cells infected with two different rSVV-SIVgag isolates (lanes 1 and 2). The amplified SIV gag DNA was detected by
agarose gel electrophoresis. M—1 kb molecular weight markers. (B) Detection of SIV gag transcripts in rSVV-SIVgag infected Vero cells by RT-PCR analysis. RT-
PCR was conducted using three different SIV gag gene primer sets and from total cell RNA template isolated from infected Vero cells. Reactions included RT (lanes 1,
3 and 5) or did not include RT (lanes 2, 4 and 6). The amplified SIV gag cDNAwas detected by agarose gel electrophoresis. M—100 bp molecular weight markers. (C)
Detection of SIV gag antigens in rSVV-SIVgag infected or wild-type SVV-infected Vero cells by immunofluorescence analysis using anti-SIV gag mAb. (D) Detection
of SIV gag antigens in uninfected Vero cells (lane 1) or in Vero cells infected with wild-type SVV (lane 2), or with two different rSVV-SIVgag viruses (lanes 3 and 4)
by immunoblot analysis using anti-SIV gag mAb. A positive control reaction included purified SIV gag antigen (lane 5).
Fig. 3. Comparison of SVV-SIVenv, SVV-SIVgag and wild-type SVV in vitro
replication. CV-1 cell monolayers in 25 cm2 flasks were infected with 800 pfu
SVV-SIVenv (▪), SVV-SIVgag (Δ) or with wild-type (wt) SVV (♦) infected
cells. The cells were harvested at 5, 24, 48 and 72 h p.i. and the infectious virus
titer per flask was determined by plaque assay on CV-1 cell monolayers. Values
are expressed as the average titer of duplicate flasks.
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The effect of insertion of the SIV genes and disruption of the
SVV gC gene on rSVV-SIVenv and rSVV-SIVgag replication in
cell culture compared to wild-type SVV was evaluated. CV-1
cell monolayers (≈2×106 cells) were infected with 800 pfu
rSVV-SIVenv, rSVV-SIVgag or wild-type SVV-infected cells
and infectious virus titer was determined at various times from 0
to 72 h p.i. The results indicated that rSVV-SIVenv and rSVV-
SIVgag replicated as efficiently as wild-type SVV in CV-1 cell
culture with nearly equivalent viral titers at 72 h p.i. (Fig. 3).
Immunization of nonhuman primates with recombinant
varicella vaccine viruses
SVV seronegative St. Kitts vervet monkeys were infected
with 5×104 pfu of rSVV-SIVenv and/or SVV-SIVgag infected
Vero cells or with the same dose of wild-type SVV by
intratracheal and subcutaneous inoculation. There was no
clinical sign of viral replication at the site of subcutaneous
injection. One animal (FV93), infected with wild-type SVV,
developed SVV viremia with a high titer of infectious SVV in
the blood between days six and ten, resulting in disseminated
infection with vesicular rash, severe hepatitis as indicated by
high serum transaminase titer on day 10 postinfection (p.i.) and
death on day 14 p.i. (Table 1). Three monkeys infected withrSVV-SIVgag (FV85, FV86, FV87), three animals infected
with rSVV-SIVenv (FV88, FV89, FV90) and two monkeys
infected with both rSVV-SIVgag and rSVV-SIVenv (FV91,
FV92) each developed a transient viremia detected only on day
6 p.i., and with a lower infectious SVV titer compared to the
animal infected with wild-type SVV. Each of the eight animals
infected with the recombinant viruses developed a vesicular
rash on day 10 to 13. Seven of eight of these animals developed
Table 1
Clinical, virological and immunological parameters of SVV infection
Monkey # Vaccine Viremia—mean pfu a Rash b Hepatitis c SVV neutralizing Ab titer d
Day 0 6 10 13 6 10 13 20 0 10 20 0 14 27 56 e
FV85 SVV-SIVgag 0 54 0 0 0 4+ 3+ 1+ 36 105 51 <20 320 640 1280
FV86 SVV-SIVgag 0 4 0 0 0 3+ 2+ 0 49 151 44 <20 320 640 1280
FV87 SVV-SIVgag 0 45 0 0 0 4+ 3+ 0 37 134 43 <20 640 1280 1280
FV88 SVV-SIVenv 0 11 0 0 0 4+ 3+ 0 29 73 44 <20 320 1280 2560
FV89 SVV-SIVenv 0 6 0 0 0 4+ 3+ 1+ 62 62 55 <20 320 1280 2560
FV90 SVV-SIVenv 0 1 0 1 0 3+ 2+ 0 31 47 48 <20 320 2560 2560
FV91 SVV-SIVenv+SVV-SIVgag 0 29 0 0 0 4+ 3+ 0 35 97 40 <20 160 640 2560
FV92 SVV-SIVenv+SVV-SIVgag 0 21 0 0 0 4+ 3+ 0 42 88 42 <20 80 640 2560
FV93 f wt SVV 0 397 443 NDg 0 4+ ND * 38 479 * <20 * * *
a Mean number of SVV pfu in PBMCs per ml blood.
b Skin rash assessed on a 1 (no rash) to 4 (severe vesicular rash) scale.
c Assessment of viral hepatitis based on elevated mean AST transaminase levels in blood.
d Antibody titers expressed as reciprocal of serum dilution that reduced SVV plaques by at least 50%.
e Two weeks following booster immunization.
f Animal died on day 14 p.i.
g Not determined.
Fig. 4. Analysis of antibody responses of immunized animals to SIV by ELISA
following primary SVV infection on day 0 and a boost immunization on day
42 pi. A lysate of purified SIV virions was used as target antigen. Open and
closed symbols denote rSVV-SIVgag and rSVV-SIVenv immunized animals,
respectively. Crossed symbols denote animals immunized with rSVV-SIVgag
and rSVV-SIVenv. Anti-SIVantibody responses on various days p.i. were tested
using monkey serum at a 1 to 20 dilution. Similar results were obtained with
monkey serum diluted 1 to 50 (data not shown).
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compared to the animal infected with wild-type SVV. Each of
the infected animals developed neutralizing antibody titers to
SVV by day 14 p.i. All of the rSVV-SIV-infected animals
resolved the SVV infection by 21 days p.i. without pathogenic
sequelae.
Six weeks after the primary infection, animals were
administered a second immunization with the same viral dose
and route of infection. None of the animals developed viremia,
skin rash or signs of hepatitis (data not shown). Six of the eight
animals had two to four fold increases in SVV neutralizing
antibody titers within 14 days following the second immuniza-
tion (Table 1).
Induction of antibody and cellular immune responses to SIV
antigens in immunized monkeys
Antibody responses of immunized monkeys to SIV antigens
were initially evaluated by ELISA using a lysate of purified
SIVmac251 virions as the target antigen (Fig. 4). rSVV-SIVenv
immunized animals generated detectable antibody responses by
27 days p.i. and the responses were stimulated by the second
immunization on day 42 p.i. Antibody responses of SVV-
SIVgag immunized animals to SIV were lower, but detectable
by 2 to 4 weeks following the boost immunization. The two
animals that were immunized with both rSVV-SIVenv and
rSVV-SIV gag generated antibody to SIV by 2 weeks p.i. and
the responses were boosted by the second immunization.
Antibody responses to the SIV gp130 and gag antigens
were confirmed by immunoblot analysis. Of the animals
immunized with rSVV-SIVenv, FV88 and FV89, but not
FV90, generated detectable antibody to the SIV env antigen by
4 weeks p.i. (Fig. 5A). The second SVV-SIVenv immunization,
6 weeks later, induced anti-SIV gp130 antibody responses by
day 14 after the boost in all three of the monkeys (FV88, FV89
and FV90) (Fig. 5B). Following rSVV-SIVgag infection, two
animals (FV85 and FV87) produced detectable humoral immuneresponses to the SIV gag antigen (Fig. 5C) by 4 weeks p.i. Anti-
SIV gag antibodies were detected in all three of the rSVV-
SIVgag immunized monkeys (FV85, FV86, FV87) at 14 days
following the second booster vaccination (Fig. 5D).
The two monkeys that were co-immunized with rSVV-
SIVenv and rSVV-SIVgag (FV91 and FV92) each generated
antibody responses to both the SIV gp130 and gag antigens
following primary infection (data not shown) and following the
second booster immunization (Fig. 6) as demonstrated by
immunoblot analysis.
To assess cell-mediated immune responses to recombinant
SIVantigen, peripheral blood mononuclear cells (PBMCs) were
harvested from each of the rSVV-SIVenv-infected animals at
various times following the second immunization and cellular
immune responses to SIVenv antigens were analyzed by IFN-γ
ELISPOT analysis. Fig. 7 demonstrates that SIV gp130 specific
Fig. 5. Detection of anti-SIV env and gag antibody responses in rSVV-SIVenv and rSVV-SIVgag immunized monkeys by immunoblot analysis. Detection of SIV
gp130 antibodies in serum (diluted 1:100) derived from SVV-SIVenv immunized monkeys FV88, FV89, and FV90 at 4 weeks p.i. (A) or 2 weeks after a second
immunization (B). Detection of SIV gag antibodies in serum (diluted 1:100) derived from SVV-SIVgag immunized monkeys FV85, FV86 and FV87 at 4 weeks p.i.
(C) or 2 weeks after a second immunization (D). Monkey sera derived before (−, pre-immune) or after immunization (+) are indicated. Serum derived from an SIV-
infected monkey (SIV) was used as a positive control serum (diluted 1:1000) for detection of the SIV gp130 (A and B) and for the 55 kDa gag protein (p55, C and D).
Secondary goat anti-monkey IgG horseradish peroxidase conjugate (diluted 1:5000) was used for detection of monkey antibodies to SIV env and gag.
Fig. 6. Detection of anti-SIV env and gag antibody responses in serum of
monkeys FV91 and FV92 by immunoblot analysis at 14 days following booster
immunization with both rSVV-SIVenv and rSVV-SIVgag. Serum (diluted
1:100) derived before (−, pre-immune) or after immunization (+) is indicated.
Serum derived from an SIV-infected monkey (SIV) was used as a positive
control serum (diluted 1:1000) for detection of the SIV gp130 and for the 55 kDa
gag protein.
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rSVV-SIVenv-infected monkeys (FV88, FV89, FV90 and
FV91) at 9 weeks following the boost immunization. Gag-
specific cellular immune responses were not detected in
monkeys FV85, FV86, FV87, FV91 and FV92 for reasons
that are unclear, but possibly due to poor stimulation or because
the assay is optimized for assessment of cellular immune
responses in rhesus macaque monkeys rather than vervet
monkeys.
Detection of rSVV DNA and SIV DNA and RNA in latent
neural ganglia
The ability of the rSVV-SIVgag and rSVV-SIVenv to
establish latent infection in neural ganglia of infected animals
was determined. Animals were sacrificed 9 weeks following
the second immunization and neural ganglia were harvested at
necropsy. SVV DNA was detected in ganglia derived from
each of the rSVV-SIVgag and rSVV-SIVenv-infected animals
by PCR and hybridization analysis using an SVV gene specific
probe (ORF 63) (Fig. 8A). The SIV gag and env genes were
maintained within the rSVV genomes as confirmed by
detection of the gag gene in ganglia derived from monkeys
infected with rSVV-SIVgag and detection of the env gene in
ganglia derived from monkeys infected with rSVV-SIVenv
(Fig. 8B shows representative results for FV92). However, the
recombinant SIV genes were not expressed in latently infected
ganglia as RT-PCR did not detect SIV gag transcripts in
ganglia derived from monkeys infected with SVV-SIVgag or
SIV env transcripts in ganglia derived from monkeys infected
with SVV-SIVenv (Fig. 8C). The SVV ORF 61 region of theSVV genome was confirmed to be transcriptionally active in
ganglia derived from monkeys FV85, FV87, FV89, FV90 and
FV91 (data not shown).
Discussion
This report demonstrates that recombinant SVV efficiently
express SIVenv and gag genes and induce immune responses to
the SIVantigens in immunized nonhuman primates. The rSVV-
SIVenv and rSVV-SIVgag induced antibody responses to the
recombinant gp130 and gag antigens, respectively, in each of the
immunized vervet monkeys. In addition, cellular immune
responses to the gp130 were detected by γ-IFN ELISPOT
Fig. 7. Detection of cellular immune responses to the SIV gp130 antigen by IFN-γ ELISPOT analysis. PBMCs (2×105 cells/well) derived from animals immunized
with SIV-SIVenv (FV88, 89, 90) or co-immunized with SVV-SIVenv and SVV-SIV gag (FV91, 92) at 9 weeks following the second immunization were stimulated in
media with (solid) or without (diagonal lines) SIV gp130 peptides.
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immunized with both rSVV-SIVenv and rSVV-SIVgag gener-
ated immune responses to both the SIV gp130 and gag antigens.
Future studies will express the SIV env and gag genes from a
single rSVV since varicella virus genomes can incorporate
multiple foreign genes (Heineman et al., 2004).
The study provides support for use of the VZV Oka vaccine
as a recombinant vehicle for immunization against other path-Fig. 8. Detection of SVV DNA and SIVenv and gag DNA and transcripts in ganglia
infected (+) and uninfected (−) Vero cells, and in neural ganglia of monkeys immuniz
of recombinant viruses (FV91, 92) by PCR and Southern blot hybridization analysis
FV85 and FV87 ganglia upon darker exposure of the film. (B) Detection of the SIV
SIVgag and rSVV-SIVenv. Control reactions include detection of gag and env DNA in
wt SVV-infected Vero cells. (C) Detection of gag and env transcripts in monkey gangl
and DIG-labeled DNA probes. SIV gag RNA was not detected in ganglia derived f
derived from monkeys FV89, 90, 91 and 92. RT-PCR reactions were conducted in th
SIV gag and env probes to gag and env PCR products, respectively.ogens. Previous studies have indicated the potential for re-
combinant varicella vaccines expressing foreign genes. A
recombinant VZV expressing the hepatitis B virus surface
antigen (HBs) induced immune responses to the VZV and HBs
antigens in immunized guinea pigs (Shiraki et al., 1991).
Immunization of guinea pigs with VZV Oka expressing the
HSV-2 glycoproteins B and D (gB and gD) induced neutralizing
antibodies against the HSV-2 antigens and immune protectionderived from latently infected monkeys. (A) Detection of SVV DNA in wt SVV-
ed with rSVV-SIVenv (FV88, 89, 90), rSVV-SIVgag (FV85, 86, 87) or with both
using an SVV gene 63 DIG-labeled probe. SVV DNAwas detected in monkey
gag and env genes within ganglia of monkey FV92 co-immunized with rSVV-
rSVV-SIVgag and rSVV-SIVenv-infected Vero cells (+), respectively, but not in
ia by RT-PCR and Southern blot hybridization using SIV gag and env primer sets
rom monkeys FV85, 87, 91 and 92. SIV env RNA was not detected in ganglia
e presence (+) or absence (−) of RT. Positive controls included hybridization of
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env gene was incorporated into the VZV Oka genome and the
recombinant vaccine virus induced immune responses to the
HIV-1 gp120 antigen in immunized guinea pigs (Shiraki et al.,
2001).
Evaluation of the ability of recombinant VZV vaccines to
induce immune protection is hampered by a lack of suitable
animal models due to the species specificity of VZV. A
recombinant VZV vaccine virus expressing the SIV gp130 did
not protect rhesus macaquemonkeys against challenge with SIV,
but rather caused enhanced disease progression (Staprans et al.,
2004). The authors speculated that the limited ability of VZV to
replicate in the monkey tissues inhibited suitable expression of
the viral and recombinant SIV env genes resulting in inefficient
induction of CD8+ T cell responses. The present study provides
support for the simian varicella model as a natural approach to
evaluate varicella vaccines.
The expression of the recombinant SIV genes in rSVV-
SIVenv and rSVV-SIVgag was controlled by the HCMV IE
promoter/enhancer, which may not be the optimal promoter for
regulating foreign gene expression in recombinant varicella
vaccines. Prolonged expression of a foreign gene in neural
ganglia may be detrimental due to toxicity or immune tolerance.
However, periodic expression may be optimal resulting in
recurrent boosting of immune responses. Indeed, occasional
subclinical reactivation of VZV from latency with the resulting
boosting of anti-VZV immune responses has been associated
with long-lasting immunity against varicella. Therefore, endo-
genous VZV promoters may be optimal for control of foreign
genes inserted into recombinant varicella vaccine viruses. The
feasibility of utilizing the simian varicella model to test this
approach is supported by construction of a recombinant SVV
expressing the green fluorescent protein under the control of the
SVV gene 29 promoter, a viral early gene (Ou and Gray, 2006).
The SIV env and gag genes were inserted into a KpnI site
within the SVV genome (nt 20,422) such that a truncated SVV
gC glycoprotein is generated. The SVV gC is nonessential for
viral replication in cell culture, but may be important in viral
pathogenesis (Gray and Byrne, 2003). HSV-1, bovine herpes-
virus type 1 (BHV-1) and equine herpesvirus type 1 (EHV-1) gC
mutants are attenuated (Kumel et al., 1985; Kúdelová et al.,
1991; Kaashoek et al., 1998; Osterrieder, 1999). The VZV gC is
associated with virion morphogenesis in the skin and VZV gC
mutants have restricted ability to replicate in skin tissue in
SCIDhu mice (Moffat et al., 1998; Storlie et al., 2006) and a
defective gC has been proposed as the basis of attenuation for the
VZV Oka vaccine (Kinchington et al., 1990). In this study, each
of the rSVV-SIVenv and rSVV-SIVgag viruses, with truncated
gCs, induced skin rash similar to that caused by wild-type SVV,
but had milder viremia and hepatitis compared to the wild-type
SVV and to values historically seen in wild-type SVV-infected
vervet monkeys. While the results suggest that truncation of the
SVV gCmay be associated with attenuation, a more direct study
comparing the virulence of SVV gC deletion mutants to that of
wild-type SVV will be required to evaluate the role of the gC in
SVV pathogenesis. Additional mutations in other viral genes
may be necessary to further attenuate recombinant varicellaviruses in order to create vaccines that do not cause skin rash and
other disease manifestations.
The rSVV-SIVenv and rSVV-SIVgag recombinant viruses,
like wild-type SVV, established latent infection in the neural
ganglia of infected monkeys. While the SIV env and gag genes
were retained within the rSVV genomes in the latent ganglia,
SIV env and gag transcripts were not detected by RT-PCR
analysis indicating that the recombinant SIV genes were not
expressed during latency. The lack of expression in ganglia
during latent infection may be due to the inability of the HCMV
IE promoter to function in neuronal cells or possibly due to
constraints from being incorporated within the viral genome.
VZV and SVV gene expression is limited to a relatively few
genes during viral latency (Kennedy et al., 1999; Gray, un-
published observation).
An estimated 40 million people worldwide are infected with
HIV and the disease continues to spread globally (United
Nations AIDS [UNAIDS], 2006). Despite intensive research an
effective HIV vaccine is unavailable and new approaches are
needed for AIDS prevention. Recent studies indicate that
recombinant herpesviruses expressing SIVantigens may reduce
viral load in SIV-infected macaque monkeys (Kaur et al., 2007).
This study has demonstrated that recombinant simian varicella
vaccines can induce humoral and cell-mediated immune
responses to SIV antigens in immunized vervet monkeys, the
species typically used to evaluate SVV pathogenesis. However,
SIVmac239, from which the recombinant SIV antigens were
derived, causes simian AIDS in rhesus macaque monkeys
(Macaca mulatta). A study is in progress to evaluate the ability
of the rSVV-SIVenv and rSVV-SIVgag to effectively immunize
rhesus monkeys and to induce immune protection against
SIVmac239 infection and simian AIDS.
Materials and methods
Cells and virus
Vero or CV-1 (African green monkey kidney) cells were
grown in Eagle's minimal essential medium (EMEM) supple-
mented with 5% newborn bovine serum, penicillin [5000 U/ml]
and streptomycin [5000 U/ml]. The Delta herpesvirus strain of
SVV was originally isolated from an infected patas monkey at
the Tulane National Primate Research Center in Covington,
Louisiana (Allen et al., 1974).
Construction of SVV-SIVenv and SVV-SIVgag recombinant
viruses
The SVV cosmid genetic system was used to generate rSVV
expressing the SIV env or gag genes (Gray and Mahalingam,
2005). The complete SIVenv ORF was amplified by PCR using
SIV env oligonucleotide primers (5′-CATCTCTAGAGTAAG-
TATGGGATGTCTTGG [forward] and 5′-TAGGTCTAGATTT-
GGCCTCACTGATACCC [reverse]) and plasmid p239SpE3′
which includes the 3′ portion of the SIVmac239 provirus
genome. The complete SIV gag ORF was PCR amplified using
SIV gag oligonucleotide primers (5′-TGTCAAGCTTCCAG-
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CTTGGACCTAACTCTATTCCTG [reverse]) and plasmid
p239SpSpE5′ which includes the 5′ end of the SIVmac239
proviral genome. ThePCRprotocolwas 94 °C for 2min followed
by 30 cycles of 94 °C for 1 min, 55 °C for 3 min and 72 °C for
3 min, followed by a final extension at 72 °C for 7 min.
The env and gag ORFs were inserted directionally into the
multiple cloning site of a cassette which included the HCMV IE
promoter/enhancer and a polyadenylation (poly A) signal se-
quence. This cassette is bracketed by KpnI restriction endonu-
clease sites permitting insertion and ligation of the HCMV-
SIVenv-polyA and HCMV-SIVgag-polyA into the unique KpnI
site of cosmid A (nucleotide 21,067 on the SVV genome). The
CosA/SIVgag or CosA/SIVenv DNA constructs were packaged
into phage heads using the MaxPlax packing system (Epicentre)
and transduced into Escherichia coli Epi305 cells. Clones were
selected on Luria-Bertani (LB) agar dishes containing ampicillin
and chloramphenicol and cosmid DNAs were obtained using a
commercial midiprep system (Qiagen Corp., Valencia, CA).
To generate the recombinant viruses, CosA/SIVgag or CosA/
SIVenv along with cosmids B, C and D were transfected into
Vero cells using the Superfect reagent and protocol (Qiagen
Corp.) (Gray and Mahalingam, 2005). Viral plaques were
evident by day 10 post-transfection and infectious rSVV clones
were propagated. Total cell DNAwas isolated from infected cells
and the presence and orientation of the SIV env or gag gene
within the SVV genome was confirmed by PCR using SIV env
and gag specific primers and by DNA sequence analyses. Total
cell RNA was isolated from infected cells and RT-PCR using
SIVenv and gag specific primers was used to confirm expression
of the SIV env and gag genes, respectively, in rSVV-infected
Vero cells.
Immunoblot and immunofluorescence analyses were used to
confirm expression of the SIV env and gag antigens in rSVV-
SIV-infected Vero cells. For immunoblot analysis, protein
lysates of rSVV-SIVenv or rSVV-SIVgag infected Vero cells
in solubilization buffer (25 mMTris–HCl, 250 mMNaCl, 5 mM
EDTA, 0.5% deoxycholate, 1.0% Triton X-100) including
protease inhibitors were fractionated by SDS polyacrylamide gel
electrophoresis (PAGE) on 10% gels and then transferred to
polyvinylidine diflouride (PVDF) membranes. SIV antigens
were detected by chemiluminescence using polyclonal monkey
SIV immune serum or mAbs to the SIV gp130 or gag antigens
(NIH AIDS Research and Reference Reagent Program),
secondary goat anti-monkey or anti-mouse IgG-horseradish
peroxidase (HRP) and chemiluminescence substrate (Pierce).
For immunofluorescence, rSVV-SIV-infected Vero cells were
seeded onto cover slips and then fixed with methanol and
permeabilized with 0.2% Triton X-100. SIV antigens were
detected by fluorescence microscopy using the SIV immune
serum and gag mAbs and secondary goat anti-mouse IgG-FITC.
Analysis of viral growth in cell culture
The in vitro growth properties of rSVV-SIVgag, rSVV-
SIVenv and wild-type SVV were compared in infected CV-1
cells. Confluent CV-1 cell monolayers (25 cm2 flasks) wereinfected with 800 plaque forming units (pfu) of rSVV-SIVgag,
rSVV-SIVenv or wild-type SVV-infected Vero cells. At 5, 24, 48
and 72 h p.i., cells were removedwith trypsin and resuspended in
media. Dilutions of infected cells were added to CV-1 cell
monolayers which were methanol fixed and stained with
methylene blue at 3 days p.i. Viral plaques were counted and
the infectious titer per flask for each time point was calculated.
Immunization of nonhuman primates with rSVV expressing SIV
antigens
St. Kitts vervet monkeys (Chlorocebus aethiops) were
confirmed to be seronegative for SVV by serum neutralization
assay prior to experimental infection. Animals were infected
with 5×104 pfu of rSVV-infected Vero cells or with the same
dose of wild-type SVV by intratracheal and subcutaneous
inoculation. Six weeks after the primary infection animals were
administered a second immunization with the same viral dose
and route of infection. After each infection, parameters of virus
infection were evaluated as previously described (Gray et al.,
1998). Viremia was assessed by harvesting PBMCs from Ficoll-
Hypaque gradients and determining infectious SVV titers by co-
culture of PBMCs on Vero cells. Skin rash was scored on an
established scale of 0 to 4+, with 0 for no rash and +4 for severe
rash. Hepatic infection was monitored by aspartate transaminase
(AST) assays of blood specimens. Animals were sacrificed by
ketamine anesthesia at 9 weeks after the second immunization.
At necropsy, tissues (liver, lung, neural ganglia) were collected
and quick-frozen for subsequent analysis.
SVV serum neutralization assay
Blood samples (4 ml) were collected from monkeys on
various days after each immunization. Humoral immune
responses to SVV were evaluated by serum neutralization of
SVV. Dilutions of monkey sera in 0.1 ml were mixed with 0.1 ml
of cell-free SVV (150 pfu) and incubated for 30 min at 37 °C.
The virus/serum mixture (0.1 ml) was then added to duplicate
CV-1 cell monolayers seeded on 12 well plates and incubated for
3 days at 37 °C. Monolayers were fixed with methanol and
stained with methylene blue and viral plaques were counted. The
serum neutralization titer was determined as the serum dilution
that reduced the viral plaque count by 50%.
Detection of humoral immune responses to SIV antigens by
ELISA and immunoblot analysis
Purified SIVmac251 virion antigen (Zeptometrix Corp.) was
bound onto microtiter plates (0.14 μg/well) in 50 μl coating
buffer (1.8 g/l NaHCO3, 2.9 g/l NaHCO3, 0.2 g/l Na2N3, pH 9.5)
at 4 °C for 6–14 h. After washing, blocking buffer (3.3% bovine
serum albumen [BSA] in phosphate buffered saline [PBS]) was
added at 4 °C for at least 4 h. SIV monkey serum was assayed at
1:20 or 1:50 dilutions in PBS with 1% BSA for 1 h at 25 °C.
Plates were washed and incubated with 100 μl/well of rabbit
anti-monkey IgG-conjugated alkaline phosphatase (Sigma-
Aldrich, diluted 1:5000) for 1 h at 25 °C. After washing,
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was added for 30 min at 25 °C and absorbance was immediately
determined at 405 nm using an ELISA microplate reader.
For immunoblot analysis, 1 μg of purified SIVmac gp130 or
gag protein (NIH AIDS Research and Reference Reagent
Program) in solubilization buffer including protease inhibitors
was fractionated by SDS–PAGE (10% gels) and then transferred
to PVDF membranes. Dilutions of monkey sera were incubated
with the membranes for 1 h at 25 °C. Following extensive
washing with phosphate buffered saline including 0.17%
Tween-20 (PBST), membranes were incubated with goat anti-
monkey-IgG-HRP secondary antibody and the presence of anti
SIV gp130 and gag antibodies was detected by chemilumines-
cence assay as described above.
Detection of cellular immune responses to SIV by ELISPOT
assay
Ninety-six well plates were coated with 1 μg/well anti-
gamma interferon (γ-IFN) mAb (U-Cytech-BV) overnight at
4 °C. Plates were washed three times with PBS and then
blocked with RPMI media including 10% fetal bovine serum for
2 h at 37 °C. Media were removed and PBMCs were added at
2×105 cells/well. The cells were stimulated in the presence or
absence of a SIVmac239 gp130 peptide pool consisting of 20
amino acid (aa) peptides (4 μg/ml per peptide) shifting by ten aa.
Cells were incubated for 24 h at 37 °C in 5% CO2. Plates were
washed with PBST after which polyclonal anti γ-IFN biotiny-
lated detector antibody solution (U-Cytech-BV) was added.
Following overnight incubation at 37 °C, the plates were washed
with PBST and stained with nitroblue tetrazolium-5-bromo-4-
chloro-3-indoylphosphate (Pierce) for 10 min. Spots were
counted and normalized to 1×106 PBMCs.
Detection of SVV and SIV nucleic acids in tissues derived from
latently infected animals
Neural trigeminal and dorsal root ganglia were harvested at
necropsy 9 weeks after the second immunization. Total cell
DNA was isolated from ganglia using a commercial kit
(Promega Corp.). rSVV genomic DNA was detected by PCR
using SVV gene 63 oligonucleotide primers (5′-GCAGG-
CGCCCCGAGATGAAATGACG [nucleotide 110,491 on the
SVV genome] and 5′-CCGTACAACATTCATCATCCG [nt
111,041 on the SVV genome]) or SIVenv and gag gene specific
primers using PCR conditions as described above.
Total cell RNA was isolated from rSVV-infected ganglia
using the TRI Reagent (Molecular Research Center). RT-PCR
was used to detect SVVand SIV gag and env transcripts in latent
ganglia using SVV ORF 61 oligonucleotide primers (5′-CTTG-
TGCAGTTAGAACAGCG and 5′-GCGTCTTTCAGCCTT-
CAACG [SVV nt 103,676 and 104,020, respectively]) or SIV
env and gag gene specific primers using conditions as described
above.
The PCR and RT-PCR results were confirmed by Southern
blot hybridization analysis. Briefly, the amplified DNA and
cDNA PCR products were fractionated by agarose gel (1.0%)electrophoresis and transferred to nylon membranes. SVV and
SIV env and gag DNA was detected by chemiluminescence
assay using digoxigenin (DIG)-labeled SVVor SIV env or gag
DNA probes, anti-DIG alkaline phosphate antibody and CSPD
substrate (Roche Applied Science).
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